Crosstalk between MicroRNA and Oxidative Stress in Primary Open-Angle Glaucoma.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
28 Feb 2021
Historique:
received: 25 01 2021
revised: 23 02 2021
accepted: 24 02 2021
entrez: 6 3 2021
pubmed: 7 3 2021
medline: 1 5 2021
Statut: epublish

Résumé

Reactive oxygen species (ROS) plays a key role in the pathogenesis of primary open-angle glaucoma (POAG), a chronic neurodegenerative disease that damages the trabecular meshwork (TM) cells, inducing apoptosis of the retinal ganglion cells (RGC), deteriorating the optic nerve head, and leading to blindness. Aqueous humor (AH) outflow resistance and intraocular pressure (IOP) elevation contribute to disease progression. Nevertheless, despite the existence of pharmacological and surgical treatments, there is room for the development of additional treatment approaches. The following review is aimed at investigating the role of different microRNAs (miRNAs) in the expression of genes and proteins involved in the regulation of inflammatory and degenerative processes, focusing on the delicate balance of synthesis and deposition of extracellular matrix (ECM) regulated by chronic oxidative stress in POAG related tissues. The neutralizing activity of a couple of miRNAs was described, suggesting effective downregulation of pro-inflammatory and pro-fibrotic signaling pathways, including nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), transforming growth factor-beta 2 (TGF-β2), Wnt/β-Catenin, and PI3K/AKT. In addition, with regards to the elevated IOP in many POAG patients due to increased outflow resistance, Collagen type I degradation was stimulated by some miRNAs and prevented ECM deposition in TM cells. Mitochondrial dysfunction as a consequence of oxidative stress was suppressed following exposure to different miRNAs. In contrast, increased oxidative damage by inhibiting the mTOR signaling pathway was described as part of the action of selected miRNAs. Summarizing, specific miRNAs may be promising therapeutic targets for lowering or preventing oxidative stress injury in POAG patients.

Identifiants

pubmed: 33670885
pii: ijms22052421
doi: 10.3390/ijms22052421
pmc: PMC7957693
pii:
doi:

Substances chimiques

MicroRNAs 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Israel Science Foundation
ID : 1545/20

Références

N Engl J Med. 2009 Mar 12;360(11):1113-24
pubmed: 19279343
Invest Ophthalmol Vis Sci. 2015 Sep;56(10):6019-28
pubmed: 26393468
J Carcinog. 2006 May 11;5:14
pubmed: 16689993
Immunity. 2007 Dec;27(6):847-59
pubmed: 18055230
Sci Rep. 2017 Apr 19;7(1):915
pubmed: 28424493
Exp Eye Res. 2008 Nov;87(5):409-14
pubmed: 18722368
Invest Ophthalmol Vis Sci. 2015 Dec;56(13):7971-82
pubmed: 26720444
Blood. 2013 Jul 11;122(2):243-52
pubmed: 23487026
Invest Ophthalmol Vis Sci. 2005 Mar;46(3):877-83
pubmed: 15728543
Cell Death Differ. 2004 Apr;11(4):372-80
pubmed: 14765132
Cell Mol Life Sci. 2012 Dec;69(23):4017-27
pubmed: 22773120
Med Sci Monit. 2020 Jan 17;26:e921514
pubmed: 31949124
Nat Commun. 2017 Oct 11;8(1):851
pubmed: 29021573
J Forensic Sci. 2019 Nov;64(6):1831-1837
pubmed: 31184791
Neuroscience. 2011 Mar 10;176:1-11
pubmed: 21187126
Invest Ophthalmol Vis Sci. 2013 May 09;54(5):3333-9
pubmed: 23599328
Int J Mol Med. 2019 Aug;44(2):503-512
pubmed: 31173163
Eur Rev Med Pharmacol Sci. 2018 Jul;22(13):4080-4089
pubmed: 30024595
Nat Cell Biol. 2009 Jun;11(6):705-16
pubmed: 19465924
Invest Ophthalmol Vis Sci. 2001 Jul;42(8):1787-94
pubmed: 11431443
J Cell Mol Med. 2020 Mar;24(6):3469-3480
pubmed: 32052937
Prog Retin Eye Res. 2006 Sep;25(5):490-513
pubmed: 16962364
Nature. 2014 Jan 16;505(7483):344-52
pubmed: 24429633
Exp Eye Res. 2015 Mar;132:73-7
pubmed: 25619138
Mol Vis. 2010 Dec 18;16:2839-46
pubmed: 21203405
Biochem Biophys Res Commun. 2018 Nov 2;505(3):677-684
pubmed: 30292407
Nat Struct Mol Biol. 2009 Jan;16(1):23-9
pubmed: 19079265
Drug Deliv. 2020 Dec;27(1):410-421
pubmed: 32133894
Br J Ophthalmol. 2004 Jun;88(6):757-60
pubmed: 15148207
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(8):3731-9
pubmed: 27415791
J Extracell Vesicles. 2019 Jun 17;8(1):1626654
pubmed: 31258880
Nat Rev Drug Discov. 2004 Mar;3(3):205-14
pubmed: 15031734
Exp Eye Res. 2020 May;194:108024
pubmed: 32246983
J Glaucoma. 2008 Jun-Jul;17(4):263-8
pubmed: 18552610
Int J Biochem Cell Biol. 2006 Mar;38(3):317-32
pubmed: 16290097
Graefes Arch Clin Exp Ophthalmol. 2020 Apr;258(4):939-941
pubmed: 31838708
Invest Ophthalmol Vis Sci. 2008 Sep;49(9):3961-9
pubmed: 18469195
J Ophthalmol. 2019 Jan 15;2019:1803619
pubmed: 30766729
Brief Funct Genomics. 2021 Mar 2;20(1):19-27
pubmed: 33165516
Invest Ophthalmol Vis Sci. 2012 Oct 09;53(11):7043-51
pubmed: 22956608
Clin Exp Ophthalmol. 2011 Apr;39(3):252-8
pubmed: 20973906
Mol Ther Nucleic Acids. 2017 Dec 15;9:48-56
pubmed: 29246323
Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5251-8
pubmed: 19516005
Oxid Med Cell Longev. 2016;2016:3164734
pubmed: 26881021
PLoS One. 2012;7(7):e39674
pubmed: 22792185
Nat Med. 2004 Jul;10 Suppl:S18-25
pubmed: 15298006
Sci Rep. 2018 Sep 28;8(1):14533
pubmed: 30266980
J Biol Chem. 2015 Sep 18;290(38):23264-81
pubmed: 26242736
Hum Mol Genet. 2018 Apr 1;27(7):1263-1275
pubmed: 29401312
Free Radic Biol Med. 2004 Sep 15;37(6):803-12
pubmed: 15384194
J Neurosci. 2008 Nov 19;28(47):12581-90
pubmed: 19020050
Semin Cell Dev Biol. 2014 Oct;34:9-14
pubmed: 24965208
Acta Ophthalmol Scand. 2004 Aug;82(4):449-53
pubmed: 15291940
Invest Ophthalmol Vis Sci. 2015 May;56(5):2993-3003
pubmed: 26024085
J Inflamm (Lond). 2017 Aug 9;14:17
pubmed: 28804270
Eye (Lond). 2011 May;25(5):587-95
pubmed: 21562585
Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1201-11
pubmed: 17325164
Int J Clin Exp Pathol. 2015 May 01;8(5):4799-806
pubmed: 26191170
Nat Commun. 2019 Apr 23;10(1):1898
pubmed: 31015515
Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):1265-1274
pubmed: 30924851
Eur Rev Med Pharmacol Sci. 2018 Jan;22(2):498-505
pubmed: 29424909
Cell Rep. 2017 Jan 31;18(5):1171-1186
pubmed: 28147273
Mol Med Rep. 2020 Mar;21(3):1606-1614
pubmed: 32016457
Oncotarget. 2017 Feb 21;8(8):13186-13194
pubmed: 28061435
Nat Commun. 2020 May 8;11(1):2315
pubmed: 32385229
Mutat Res. 2006 Mar;612(2):105-14
pubmed: 16413223
Molecules. 2011 Jun 27;16(7):5402-21
pubmed: 21709622
J Proteome Res. 2010 Sep 3;9(9):4831-8
pubmed: 20666514
ALTEX. 2020 Jan 27;37(2):265-274
pubmed: 32052854
Trends Mol Med. 2013 Oct;19(10):586-93
pubmed: 23876925
Invest Ophthalmol Vis Sci. 2011 Jun 01;52(6):3567-72
pubmed: 21273536
Mol Vis. 2009 Nov 28;15:2488-97
pubmed: 19956414
Stem Cell Res Ther. 2013 Apr 25;4(2):34
pubmed: 23618405
Pharmacology. 2018;102(3-4):213-222
pubmed: 30099456
Mol Aspects Med. 2004 Feb-Apr;25(1-2):5-16
pubmed: 15051312
Curr Opin Pharmacol. 2013 Feb;13(1):16-22
pubmed: 22999653
Neuroscience. 2009 Jan 23;158(2):610-6
pubmed: 18996448
Nat Commun. 2018 Aug 10;9(1):3209
pubmed: 30097565
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1758-1765
pubmed: 31062616
Curr Eye Res. 2010 Apr;35(4):295-301
pubmed: 20373896
Biochim Biophys Acta. 2013 May;1830(5):3217-66
pubmed: 23036594
Am J Med. 2003 Jun 1;114(8):638-46
pubmed: 12798451
PLoS Genet. 2012;8(5):e1002611
pubmed: 22570627
J Clin Med. 2020 Sep 30;9(10):
pubmed: 33007927
Braz J Med Biol Res. 2013 Oct;46(10):824-30
pubmed: 24141609
J Proteome Res. 2019 Mar 1;18(3):1307-1315
pubmed: 30701980
Cell Mol Neurobiol. 2018 Jul;38(5):1021-1031
pubmed: 29302837
Int J Mol Sci. 2020 Aug 25;21(17):
pubmed: 32854215
Int J Biomed Sci. 2008 Jun;4(2):89-96
pubmed: 23675073
Invest Ophthalmol Vis Sci. 2014 Oct 28;55(11):7433-40
pubmed: 25352117
Invest Ophthalmol Vis Sci. 2004 Sep;45(9):3107-12
pubmed: 15326127
Cell Death Differ. 2018 Jan;25(1):180-189
pubmed: 28885615
J Neurochem. 2006 Jun;97(6):1634-58
pubmed: 16805774
J Cell Physiol. 2019 Jun;234(6):8873-8887
pubmed: 30515784
Eur J Pharm Biopharm. 2015 Sep;95(Pt B):182-93
pubmed: 25676338
PLoS One. 2019 Sep 6;14(9):e0221942
pubmed: 31490976
Front Pharmacol. 2020 Jul 14;11:1012
pubmed: 32765258
Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3177-87
pubmed: 16123417
Invest Ophthalmol Vis Sci. 2019 Jul 1;60(8):2925-2934
pubmed: 31284309
Oxid Med Cell Longev. 2017;2017:9208489
pubmed: 28194256
Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5368-5377
pubmed: 29049738
J Cereb Blood Flow Metab. 2015 Mar;35(3):412-23
pubmed: 25515214
Arch Ophthalmol. 2005 Apr;123(4):458-63
pubmed: 15824217
Mol Vis. 2009;15:523-33
pubmed: 19279690
JAMA. 2014 May 14;311(18):1901-11
pubmed: 24825645
Glia. 2018 Nov;66(11):2267-2278
pubmed: 29726599
Int J Biol Macromol. 2018 Dec;120(Pt A):801-810
pubmed: 30170060
J Neuroinflammation. 2012 May 14;9:92
pubmed: 22583833
Mitochondrion. 2017 Sep;36:186-192
pubmed: 28866056
BMC Mol Biol. 2014 Nov 18;15:25
pubmed: 25406880
Exp Eye Res. 2009 Apr;88(4):769-75
pubmed: 19114037
Nat Immunol. 2014 Apr;15(4):393-401
pubmed: 24608041
PLoS One. 2015 Jul 17;10(7):e0133582
pubmed: 26186651
J Ocul Pharmacol Ther. 2015 Mar;31(2):63-77
pubmed: 25587905
Annu Rev Vis Sci. 2018 Sep 15;4:45-77
pubmed: 29852094
Nat Med. 2001 Mar;7(3):304-9
pubmed: 11231628
Oxid Med Cell Longev. 2018 Apr 12;2018:4968321
pubmed: 29849898
Invest Ophthalmol Vis Sci. 2011 May 01;52(6):3391-7
pubmed: 21330653
Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2533-41
pubmed: 16723467
J Hum Genet. 2017 Jan;62(1):105-112
pubmed: 27412874
Exp Eye Res. 2007 Mar;84(3):389-99
pubmed: 17196589
Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):2884-2890
pubmed: 28586912
Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1454-1466
pubmed: 29625468
Stem Cell Res. 2013 May;10(3):301-12
pubmed: 23399448
J Biol Chem. 2004 Apr 23;279(17):17197-204
pubmed: 14963044
Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):154-165
pubmed: 29332130
Blood. 2020 Jan 16;135(3):167-180
pubmed: 31805184
Stem Cell Res. 2013 Jul;11(1):657-67
pubmed: 23688833
Cornea. 2016 Nov;35(11):1466-1470
pubmed: 27490049
Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6441-7
pubmed: 20592224
Mol Med Rep. 2016 Dec;14(6):5746-5750
pubmed: 27878244
Oxid Med Cell Longev. 2017;2017:8416763
pubmed: 28819546
Exp Eye Res. 2017 Jul;160:62-84
pubmed: 28499933
Exp Eye Res. 2020 Nov;200:108197
pubmed: 32871166
Acta Ophthalmol. 2020 Sep;98(6):e768-e772
pubmed: 32043817
J Immunoassay Immunochem. 2020 May 3;41(3):257-271
pubmed: 32046582
BMC Ophthalmol. 2020 Mar 16;20(1):104
pubmed: 32178636
J Mol Cell Biol. 2017 Aug 1;9(4):289-301
pubmed: 28655163
Biochem Pharmacol. 2006 Nov 30;72(11):1493-505
pubmed: 16723122
Invest Ophthalmol Vis Sci. 2004 Nov;45(11):4049-59
pubmed: 15505055
Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2955-2966
pubmed: 30025119
Ann N Y Acad Sci. 2002 Apr;959:14-23
pubmed: 11976181
Int J Mol Sci. 2020 Mar 27;21(7):
pubmed: 32230793
Invest Ophthalmol Vis Sci. 2019 Sep 3;60(12):3854-3862
pubmed: 31529118
Sci Rep. 2018 Feb 28;8(1):3817
pubmed: 29491350
Am J Ophthalmol. 2004 Jan;137(1):62-9
pubmed: 14700645
Clin Chim Acta. 2019 Aug;495:529-537
pubmed: 31153869
Brain Res. 2008 Jan 10;1188:35-43
pubmed: 18053973
Trends Mol Med. 2004 Nov;10(11):549-57
pubmed: 15519281
Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3826-32
pubmed: 19339745
Nat Med. 2005 Dec;11(12):1306-13
pubmed: 16286925
Glia. 2000 Apr;30(2):178-86
pubmed: 10719359
Eur Rev Med Pharmacol Sci. 2018 Sep;22(17):5416-5423
pubmed: 30229811
Brain Behav Immun. 2019 May;78:188-201
pubmed: 30685530
J Ocul Biol. 2014 May;2(1):
pubmed: 25356439
Int J Mol Sci. 2020 Feb 13;21(4):
pubmed: 32070041
EMBO Rep. 2015 Jan;16(1):24-43
pubmed: 25488940
Biochem Biophys Res Commun. 2015 May 1;460(2):164-9
pubmed: 25757910
Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3173-3182
pubmed: 31081068
Biomaterials. 2016 Jun;91:151-165
pubmed: 27031810
J Cell Physiol. 2018 Oct;233(10):6630-6637
pubmed: 29226948
Mol Vis. 2008 Jan 31;14:224-33
pubmed: 18334938
Nat Commun. 2017 May 25;8:15201
pubmed: 28541289
Exp Mol Pathol. 2019 Feb;106:109-115
pubmed: 30594603
Invest Ophthalmol Vis Sci. 2002 Jul;43(7):2236-43
pubmed: 12091422
PLoS One. 2012;7(12):e51688
pubmed: 23272142
Cell Tissue Res. 2012 Jan;347(1):279-90
pubmed: 22101332
Int Immunopharmacol. 2020 Jun;83:106395
pubmed: 32199351
Mol Cell Biol. 2011 Oct;31(19):4087-96
pubmed: 21807897
AIMS Mol Sci. 2016;3(2):196-221
pubmed: 27239555
Toxicol Res (Camb). 2017 Aug 24;6(6):878-888
pubmed: 30090550
Invest Ophthalmol Vis Sci. 2010 Jun;51(6):2976-85
pubmed: 20053980

Auteurs

Saray Tabak (S)

Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.

Sofia Schreiber-Avissar (S)

Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.

Elie Beit-Yannai (E)

Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH